Table 3.
Antibiotics susceptibility of Pseudomonas aeruginosa and P. putida keratitis during the 1998–2017 period
| Antibiotics |
P. aeruginosa
(n = 33) |
P. putida
(n = 16) |
p-value (x2-test) |
|---|---|---|---|
| Beta-lactams | |||
| Ticarcillin | 17/20 (85.0) | 0/7 (0.0) | < 0.001* |
| Tic/clav | 20/27 (74.1) | 0/16 (0.0) | < 0.001 |
| Piperacillin | 28/29 (96.6) | 12/16 (75.0) | 0.047* |
| Pip/tazo | 18/19 (94.7) | 12/16 (75.0) | 0.156* |
| Carbenicillin | 10/14 (71.4) | – | – |
| Amp/sul | 0/17 (0.0) | 0/12 (0.0) | – |
| Cefotaxime | 0/28 (0.0) | 1/16 (6.3) | 0.364* |
| Ceftazidime | 31/33 (93.9) | 14/16 (87.5) | 0.588* |
| Cefepime | 30/31 (96.8) | 15/16 (93.8) | 1.000* |
| Aztreonam | 16/29 (55.2) | 1/16 (6.3) | 0.001 |
| Imipenem | 33/33 (100.0) | 13/16 (81.3) | 0.030* |
| Meropenem | 28/28 (100.0) | 14/16 (87.5) | 0.127* |
| Aminoglycosides | |||
| Amikacin | 30/33 (90.9) | 16/16 (100.0) | 0.541* |
| Gentamicin | 30/33 (90.9) | 15/16 (93.8) | 1.000* |
| Tobramycin | 14/15 (93.3) | 7/7 (100.0) | 1.000* |
| Netilmicin | 2/2 (100.0) | 3/4 (75.0) | 1.000* |
| Isepamicin | 2/2 (100.0) | 3/4 (75.0) | 1.000* |
| Fluoroquinolones | |||
| Ciprofloxacin | 28/29 (96.6) | 14/16 (87.5) | 0.285* |
| Levofloxacin | 6/7 (85.7) | 6/7 (85.7) | 1.000* |
| Others | |||
| Pipemidic acid | 3/4 (75.0) | – | – |
| Tigecycline | 2/16 (12.5) | 1/9 (11.1) | 1.000* |
| TMP/SMX | 0/28 (0.0) | 0/16 (0.0) | – |
| Colistin | 18/18 (100.0) | 15/15 (100.0) | – |
Tic/clav = ticarcillin/clavulanate; Pip/tazo = piperacillin/tazobactam; Amp/sul = ampicillin/sulbactam;
TMP/SMX = trimethoprim/sulfamethoxazole
Values are presented as n1/n2 (%), where n1 is the number of isolates with susceptibility and n2 is the number of tested isolates
*The p-value was calculated using Fisher’s exact test